Collegium Pharmaceutical Inc (COLL) Expected to Post Earnings of -$0.10 Per Share

Equities research analysts predict that Collegium Pharmaceutical Inc (NASDAQ:COLL) will report earnings per share of ($0.10) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Collegium Pharmaceutical’s earnings, with estimates ranging from ($0.21) to ($0.04). Collegium Pharmaceutical posted earnings per share of ($0.54) during the same quarter last year, which would suggest a positive year over year growth rate of 81.5%. The business is scheduled to announce its next quarterly earnings report on Wednesday, March 6th.

On average, analysts expect that Collegium Pharmaceutical will report full year earnings of ($0.85) per share for the current financial year, with EPS estimates ranging from ($0.96) to ($0.79). For the next year, analysts forecast that the business will post earnings of $0.54 per share, with EPS estimates ranging from $0.12 to $0.87. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.14). The firm had revenue of $70.20 million during the quarter, compared to the consensus estimate of $74.79 million. Collegium Pharmaceutical had a negative return on equity of 70.06% and a negative net margin of 30.13%. The firm’s revenue for the quarter was up 485.0% compared to the same quarter last year. During the same period last year, the company earned ($0.45) EPS.

Several analysts have issued reports on COLL shares. Cantor Fitzgerald dropped their target price on Collegium Pharmaceutical from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, August 9th. BidaskClub cut Collegium Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 18th. HC Wainwright reaffirmed a “buy” rating on shares of Collegium Pharmaceutical in a research report on Monday, September 17th. Zacks Investment Research cut Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, October 23rd. Finally, ValuEngine raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Tuesday, November 13th. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $31.71.

NASDAQ COLL traded down $0.27 during midday trading on Friday, hitting $19.41. 16,592 shares of the company traded hands, compared to its average volume of 482,212. The company has a current ratio of 0.78, a quick ratio of 0.75 and a debt-to-equity ratio of 4.17. The stock has a market capitalization of $641.68 million, a PE ratio of -7.92 and a beta of 0.29. Collegium Pharmaceutical has a 52 week low of $13.70 and a 52 week high of $29.90.

In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction on Monday, October 15th. The stock was sold at an average price of $16.53, for a total transaction of $413,250.00. Following the sale, the director now owns 361,000 shares of the company’s stock, valued at approximately $5,967,330. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 25.76% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC purchased a new position in Collegium Pharmaceutical in the 2nd quarter worth $213,000. Atria Investments LLC raised its stake in Collegium Pharmaceutical by 81.3% in the 3rd quarter. Atria Investments LLC now owns 15,307 shares of the specialty pharmaceutical company’s stock worth $226,000 after acquiring an additional 6,866 shares during the last quarter. Jefferies Group LLC purchased a new position in Collegium Pharmaceutical in the 3rd quarter worth $271,000. Capital Fund Management S.A. purchased a new position in Collegium Pharmaceutical in the 3rd quarter worth $286,000. Finally, Man Group plc purchased a new position in Collegium Pharmaceutical in the 3rd quarter worth $287,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Read More: Hedge Funds – Risk or Reward?

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply